As part of its strategic focus on building a continuum of care within
the oncology space,
The acquisition immediately enhances AngioDynamics’ Oncology business, adding a commercialized, clinically proven product that minimizes the occurrence of pneumothorax, or PTX, the most common complication of CT-guided percutaneous lung biopsy1. The technology delivers a proprietary hydrogel plug, which prevents air leakage during a CT-guided percutaneous lung biopsy and helps mitigate the risk of PTX. In 2010, a published clinical trial involving 339 patients at 15 different sites showed BioSentry technology with an 85% clinical success rate, compared to 69% in the control group1.
“The addition of the BioSentry technology to our oncology portfolio is
the type of strategic and thoughtful acquisition that aligns with our
plans to deliver safer, clinically relevant, and economically favorable
solutions that improve patient outcomes,” said
Approved by the
BioSentry’s trailing 12-months revenues exceeded
SunTrust Robinson Humphrey served as the exclusive financial advisor to
Vascular Access Business
In May of 2017,
As a result of last week’s ruling, AngioDynamics’ antitrust lawsuit against Bard will proceed.
Tip location systems are devices that can be used to aid healthcare
professionals in the bed-side placement of a PICC. The lawsuit claims
that Bard has a dominant position in the tip location system market and
will only sell the proprietary stylet necessary to operate its tip
location systems preloaded in its PICCs, not separately, which would
allow any type of PICC to be used with the tip location systems. By
doing so, customers who want to buy Bard's tip location systems must
also buy Bard's line of PICCs, which prevents hospitals and other
medical providers from purchasing BioFlo PICCs from
AngioDynamics’ lawsuit seeks to end Bard's violation of the antitrust
laws and to recover treble damages for losses due to Bard’s violations,
as well as attorneys' fees and other costs.
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
1 J Vasc Interv Radiol. 2010 Aug;21(8):1235-43.e1-3.